Ger Brophy is the Interim Chief Executive Officer of ElevateBio and a member of its Board of Directors. He previously served as a strategic advisor to the Company’s leadership team and CEO.
by
Management Team
Bhakti has more than 20 years of experience in biotech, consulting, and financial services including corporate finance, business development, strategy, and business process re-engineering. Bhakti joined ElevateBio as one of earliest employees and has been leading the finance team since 2018.
Jacob Abrams joined ElevateBio in 2020, and as general counsel, he leads the Company’s legal function.
Catherine Hu joined ElevateBio in 2021 to lead the Company’s investor relations and corporate affairs functions. Prior to ElevateBio, Catherine led investor relations, corporate affairs, and patient advocacy functions at Scholar Rock, Inc. and was part of the investor relations team at Alexion Pharmaceuticals.
Katie Jorgensen joined ElevateBio in 2021 and as Site Head at BaseCamp, she is responsible for supply chain, facilities, technical operations, manufacturing, and program management supporting strategic contracts and valued partnerships bringing innovative cell and gene therapies to patients. Previously, she was the Company’s VP, Commercial Operations and CMC Program Management.
Tess Kitchener has twenty years of experience in biotech, with the majority in CMC leadership roles, including those in process development, manufacturing technical support, and manufacturing. Currently, Tess is leading the BaseCamp Commercial team and is responsible for Business Development, Marketing and Commercial Operations for BaseCamp.
Missy has more than 15 years of experience in operations and people strategies. As a strategic thought partner to the leadership team, she identifies areas for operational improvement, provides insight and analysis on company strategy and operations, and ensures a continued focus on top priorities across the company.
Aaron Nudelman joined ElevateBio in 2020, and as SVP, Head of Intellectual Property, he leads the Company’s IP function overseeing patent preparation, prosecution, maintenance, and enforcement; IP diligence and strategy; and IP aspects of license negotiation and related transactions.
Michael has spent the last twenty years in biotechnology building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late-stage clinical trials. Currently, Michael is the Chief Technology Officer at ElevateBio BaseCamp and is responsible for BaseCamp’s technology offerings, including cell therapy, LentiPeakTM platform, and process development.
Amy leads research and development at Life Edit Therapeutics. She has more than 20 years of scientific leadership and expertise with an extensive background in genetic medicine, neuroscience, drug development, and scientific strategy.
Heidi Wagner leads the Company’s global government affairs function, playing a key role in the continued national and global expansion of our technology platforms and biomanufacturing network. Heidi has more than 20 years of experience in establishing and executing global strategies across government affairs, public policy, and patient advocacy.
